Skip to content
Menu

AnaptysBio, Inc. ANAB

Full chart Compare
Set alert

Price alert · ANAB

All alert types
46.63 USD -0.77 (-1.62%)

Regular-session close

46.63 0.00 0.00%

After hours · Nov 20, 4:38 PM ET

46.05 Day range 47.66
25.11 52-week range 69.81
YTD
+44.28%
1 year
+85.70%

Fundamental scorecard

9 of 25 checks passed on ANAB’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 2 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 2 of 5

  • No data:P/E below its own 5-year median P/E 7.5. Not enough data to decide.
  • Passed:P/E under 20 P/E 7.5: an earnings yield of 13.3%.
  • Passed:Price to sales below its own 5-year median Price to sales 7.2 against a 5-year median of 15.1.
  • Failed:Price to book below its own 5-year median Price to book 66.6 against a 5-year median of 5.7.
  • Failed:Free cash flow yield above 4% Free cash flow of 36.0M is 2.6% of the market value.

Growth 3 of 5

  • Passed:Revenue grew over the last year Revenue of 192M is +13.0% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +25.6% a year from FY 2020 to FY 2025.
  • Passed:Earnings per share grew over the last year EPS 5.33 against -2.56 in the 12 months before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -0.73 in FY 2020, -0.44 in FY 2025.
  • Failed:Analysts expect higher earnings per share over the next year The average forward estimate is -17.4% on the last 12 months.

Profitability 2 of 5

  • Passed:Profitable over the last year Net income of 184M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • No data:Return on equity above 15% Not enough data to decide.
  • Passed:Net margin above its 5-year average Net margin of 96.3% against a 5-year average of -492.2%.
  • Failed:Free cash flow is at least 80% of net income Free cash flow of 36.0M is 19.5% of net income.

Financial health 2 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 188M against short-term liabilities of 22.4M.
  • Failed:Short-term assets cover long-term liabilities Short-term assets of 188M against long-term liabilities of 264M.
  • Failed:Net debt under 40% of equity Net debt of 109M is 525.4% of equity.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of 35.9M is 13.7% of debt.
  • Passed:Operating profit covers interest at least 3 times No interest expense reported.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What ANAB owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 307M of assets

Debt, equity and cash by year

Now: 109M of debt after cash

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

2.13 Grey zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

6 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

B3 / 5 overall

  • DCF 1
  • Return on Equity 5
  • Return on Assets 5
  • Debt / Equity 2
  • P/E 3
  • P/B 1

Valuation

P/E -70.3×
P/S 3.8×
P/B 24.1×
P/FCF 45.8×
EV/EBITDA 9.7×
EV/Sales 2.9×
FCF Yield 2.2%

Profitability

Gross Margin 99.0%
Operating Margin 20.4%
Net Margin -5.6%
ROE -35.6%
ROIC 14.6%
ROA -3.6%

Growth (YoY)

Revenue 157.0%
Operating Income 141.7%
EPS (diluted) 91.0%
Free Cash Flow 114.5%

Financial Health

Current Ratio 9.1×
Quick Ratio 9.1×
Debt / Equity 0.4×
Net Debt / EBITDA -3.2×
Interest Coverage 0.6×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31